Mepolizumab therapy decreases epithelial-derived cytokine concentrations in exhaled breath condensates from patients with severe eosinophilic asthma
- PMID: 37055938
- DOI: 10.1111/cea.14316
Mepolizumab therapy decreases epithelial-derived cytokine concentrations in exhaled breath condensates from patients with severe eosinophilic asthma
Keywords: IL-25; IL-33; anti-IL-5 treatment; asthma; exhale breath condensates; mepolizumab; periostin.
References
REFERENCES
-
- Nowak-Jurek A, Gajewski A, Frachowicz-Guereirro K, et al. Cytokines in serum, nasal secretion and exhaled breath condensate during mepolizumab therapy in patients with different phenotypes of severe eosinophilic asthma: a pilot study. Clin Exp Allergy. 2022;52(12):1444-1447. doi:10.1111/cea.14231
-
- Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, Miliauskas S, Malakauskas K. Serum levels of epithelial-derived cytokines as Interleukin-25 and thymic stromal lymphopoietin after a single dose of mepolizumab in patients with severe non-allergic eosinophilic asthma: a short report. Can Respir J. 2019;2019:7. doi:10.1155/2019/8607657
-
- De Schryver E, Derycke L, Calus L, et al. The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology. 2017;55(2):152-160. doi:10.4193/Rhino16.314
-
- Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. doi:10.1111/all.14318
-
- Sonnenberg-Riethmacher E, Miehe M, Riethmacher D. Periostin in allergy and inflammation. Front Immunol. 2021;12:722170. doi:10.3389/fimmu.2021.722170
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical